<DOC>
	<DOC>NCT00095758</DOC>
	<brief_summary>This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive Disorder.</brief_summary>
	<brief_title>A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Men and women, 1865 years old Experienced a Major Depressive Disorder with the current episode of minimally 8 weeks in duration. Treatment history of an inadequate response to at least one and no more than three antidepressants.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>